North American Cannabis Holdings, Inc. (USOTC: USMJ) and Puration, Inc. (USOTC: PURA) today announced that majority shareholder and veteran Central Intelligence Agency (CIA) Operations Officer Edward Bollen will speak at the upcoming Southwest Cannabis Conference and Expo (SWCC) in Fort Worth, Texas April 22-23 on the subject of America’s current opioid epidemic. Deaths from opioid overdoes are at an all time high with 165,000 people dying form prescription opioid overdoes alone since 1999. Cannabis provides a safe alternative to many of the ailments treated with prescription opioids.
Mr. Bollen will participate in a panel discussion on the opioid epidemic bringing his 33 years of U.S. Government service experience in multiple National Security fields. Mr. Bollen has extensive experience in military special operations, law enforcement investigations and covert action. He has traveled to, worked in or lived in over 70 different countries throughout his career. His career started in the U.S. Marine Corps where his service included a 3-year tour of duty as a military aid to the White House. Mr. Bollen transitioned from the Marines to begin a 26 year career with the Central Intelligence Agency (CIA) as an Intelligence Operations Officer where he held several senior management positions both domestic and abroad. He has served in Africa, the Middle East, Central Eurasia, Asia, and South America.
In addition to his founding role at USMJ, Mr. Bollen works today as a threat assessment consultant, corporate security advisor and security team leader for industrial physical and personal requirements. Mr. Bollen recently worked as a consultant on the History Channel series “Selection: Special Operations Experiment” which provided some unclassified insight into how the America’s elite commands select candidates for service in Special Forces units.
“I’m proud of the work USMJ has accomplished in the evolving legal cannabis sector,” said Mr. Bollen, majority shareholder and co-founder. “The company has experimented and trialed a number of different enterprises across this diverse and ever changing landscape. One can’t be an entrepreneur in this market sector without also being a socially responsible advocate for the real benefits cannabis has to bring to the communality and economy. I believe you will find here at USMJ that we are committed to doing our part, and we invite all to come see for themselves at the Southwest Cannabis Conference and Expo in Fort Worth next week.”
USMJ is presenting its fast casual concept restaurant, the AmeriCanna Cafe, at the Southwest Cannabis Conference and Expo and featuring its sports and fitness nutritional supplement product line, EVERx with licensed products produced by Puration to include EVERx CBD Infused Bottled Sports Water, EVERx Alkaline Bottled Sports Water, and EVERx CBD Infused Gummies for Post Workout Recovery.
Puration recently announced that NCM Biotech has licensed to PURA the right to utilize NCM Biotech’s patented cannabis extraction process to produce cannabis extracts for infusion into recreational, fitness wellness, alternative medicine and beauty products. NCM Biotech exclusively owns U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” The license of the process to PURA is the first and only license NCM Biotech has executed. NCM and its founder Frederick Ferri will also be at the Southwest Cannabis Conference and Expo.
Learn More About USMJ: growusmj.com
Learn More About PURA: purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Brian Shibley, CEO
North American Cannabis Holdings Contact: